Close Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

Kairos Ventures

Investor type Venture Capital
Founders James Demetriades

Overview

Unlock datapoints

Portfolio analytics

Team

Investments

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 53
Average round size
info
The average size of a deal this fund participated in
$7M
Portfolio companies 44
Rounds per year 7.57
Lead investments 4
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.17
Exits 1
Key employees 3

Areas of investment

  • Biotechnology
  • Health Care
  • Therapeutics
  • Medical
  • Pharmaceutical
Summary

Kairos Ventures is the famous VC, which was founded in 2015. The leading representative office of defined VC is situated in the Beverly Hills. The company was established in North America in United States.

The usual cause for the fund is to invest in rounds with 1-2 partakers. Despite the Kairos Ventures, startups are often financed by Tech Coast Angels, Foundation Venture Capital Group, The Angels' Forum. The meaningful sponsors for the fund in investment in the same round are Spruce Capital Partners, Penn Medicine Co-Investment Fund, DEFTA Partners. In the next rounds fund is usually obtained by Spruce Capital Partners, BASF Venture Capital, Vesalius Biocapital Partners.

This organization was formed by James Demetriades. The overall number of key employees were 3.

Speaking about the real fund results, this VC is 25 percentage points more often commits exit comparing to other organizations. The important activity for fund was in 2017. Despite it in 2019 the fund had an activity. This Kairos Ventures works on 26 percentage points less the average amount of lead investments comparing to the other organizations. The usual things for fund are deals in the range of 10 - 50 millions dollars. The top amount of exits for fund were in 2015. The fund is generally included in 7-12 deals every year.

Among the most popular portfolio startups of the fund, we may highlight Axial Biotherapeutics, Provivi, Neuro-Bio. Besides, a startup requires to be at the age of 4-5 years to receive the investment from the fund. The fund has no specific favorite in a number of founders of portfolio startups. When startup sums 5+ of the founder, the probability for it to get the investment is little. For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States. We can highlight the next thriving fund investment areas, such as Renewable Energy, Health Care.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of Kairos Ventures:
Typical Co-investors
Kairos Ventures is more likely to invest in rounds together with the following funds:
There are no funds here. If we find new data, we will add it here.
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after Kairos Ventures:
There are no funds here. If we find new data, we will add it here.

Look at other 50 related and similar funds Collapse list
Fund NameLocation
AAC Capital Partners Amsterdam, Noord-Holland, The Netherlands
Alliance Trust Dundee, Dundee City, United Kingdom
Center for the Advancement of Science in Space Florida, Merritt Island, United States
CITIC M&A Fund Beijing, Beijing, China
EduLab Japan, Tokyo
Gongdao Chuangxin Beijing, Beijing, China
Hongzhao Fund China, Futian District, Guangdong Province
Landmark Partners Connecticut, Simsbury, United States
Liguo Chuangjing Beijing, Beijing, China
Macnica Ventures -
MISAWA HOMES Japan, Tokyo
Morgan Noble District of Columbia, United States, Washington
NE Angels -
Nutty Capital Venture China, Hong Kong, Hong Kong Island
Share Capital Partners China, Guangdong, Shenzhen
StarterStudio -
The Crawford Group Missouri, St Louis, United States
UltimateVC Cyprus, Limassol
Virtue Inno Valley Beijing, China, Haidian

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

Tulu

Artificial Intelligence
Communities
Consumer Goods
Internet of Things
Machine Learning
Property Management
Sharing Economy
$3M13 Apr 2021 New York, New York, United States

Vivodyne

Biotechnology
Lifestyle
Medical
$2M11 Mar 2021 Philadelphia, Pennsylvania, United States

AetherTouch

Software
03 Mar 2021 -

Novosteo

Health Care
Pharmaceutical
$5M13 Jan 2021 Pennsylvania, United States

Agriculture
Biotechnology
Chemical
$45M22 Dec 2020 Santa Monica, California, United States

Foldax

Developer Platform
Manufacturing
Medical Device
$20M22 Jun 2020 Salt Lake City, Utah, United States

FGC Plasma Solutions

Aerospace
Energy
Fuel
Search Engine
22 May 2020 Cleveland, Ohio, United States

PteroDynamics

Manufacturing
01 Jan 2020 Ventura, California, United States

Pinpoint Therapeutics

Biotechnology
Health Care
Pharmaceutical
Therapeutics
$1M30 Dec 2019 Philadelphia, Pennsylvania, United States
News
Novosteo Closes $5.5M in Series A Financing

– Novosteo Closes $5.5m in Series A Financing.
– The company raised $5.5m in Series A financing.
– The round was led by Kairos Ventures, as well as BioCrossroads Ventures, Elevate Ventures and Purdue Research Foundation.
– Proceeds from the financing will be used to advance NOV004 into clinical development that will begin in the first half of 2021.

Research Bridge Partners' Portfolio Company, Novosteo, Inc., Closes $5.5 Million in Series A Financing

– Research Bridge Partners announced that one of its portfolio companies, Novosteo, Inc., closed $5.5m in Series A financing to further development of the first-ever targeted bone anabolic agent NOV004.
– The round was led by Kairos Ventures, as well as BioCrossroads Ventures, Elevate Ventures and Purdue Research Foundation.
– Novosteo, Inc.’s NOV004 has shown promise in live animals in the acceleration of fracture healing when delivered systemically.
– Proceeds from the financing will be used to advance NOV004 into clinical development that will begin in the first half of 2021.
– Bone injuries and disease are one of the most challenging health issues facing all ages, especially for the elderly.

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Kairos Ventures?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

Wait!
You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: